Jack supports clients with evidence-based research and analysis that spans healthcare sectors and stakeholders.

With a background in health economics, statistical analysis, and health policy, he contributes to the development of client analysis and insights.

Jack’s background in health policy and health economics includes varied research experiences. As a Congressional intern, he attended and transcribed financial services and healthcare policy hearings to support the development of legislative agendas. At the National Community Pharmacy Association, he performed economic research on nationwide drug pricing trends and analyzed the impact of health policy and associated data for impacts to pharmaceutical stakeholders at the regional and state levels. Additionally, at First Horizon National Corporation, he assisted in a wide range of compliance and due-diligence projects within the department of mergers and acquisitions.

Jack has a BS in economics from the George Washington University.

Authored Content

Medicare offers an add-on payment to facilities furnishing qualified new and innovative renal dialysis equipment and supplies via the Transitional Add-on Payment Adjustment for New and Innovative Equipment and Supplies (TPNIES).

The TDAPA supports payment and patient access to new therapies introduced to the End-Stage Renal Disease (ESRD) Prospective Payment System (PPS). While no major TDAPA revisions were finalized in the Calendar Year (CY) 2021 ESRD PPS Final Rule, stakeholders should continue to monitor this payment adjustment policy, as it has evolved since its introduction and may continue to change in future rulemaking cycles.

The ESRD Treatment Choice model demonstrates an increased focus on improving health outcomes for Medicare patients receiving dialysis by realigning incentives to favor the adoption of home dialysis and increasing the rate at which patients receive kidney transplants. This mandatory model could lead to significant disruption for stakeholders in the coming years. Understanding the risk and opportunities associated with this model will be critical for patients, providers, and manufacturers alike.

On August 25, “Calcimimetic Use in Dialysis-Dependent Medicare Fee-for-Service Beneficiaries and Implications for Bundled Payment” was published in Kidney 360. The article featured research and analytics conducted by Avalere experts.

Globally, the need to flatten the epidemic curve of COVID-19 cases has become the top public health priority to save lives and minimize the burden on the health care system. In the absence of treatments and prophylactics for the novel coronavirus, social distancing and quarantine strategies continue to be implemented in the US.

As the Coronavirus Disease 2019 (COVID-19), caused by the novel SARS-CoV-2 virus, rapidly spreads through the US, media and public scrutiny over the current diagnostic testing landscape has increased, given that the US lags behind other countries in the number of tests performed and turnaround time for results reported.